Start-up Cerebri GmbH - 05/08/2024

Comprehensive EEG supply thanks to telemedicine

Fewer and fewer patients are getting timely access to electroencephalograms, as the process of measuring brain activity and interpreting the results requires specific expertise. Cerebri GmbH, a newly established Tübingen-based company, aims to address this issue by offering user-friendly EEG caps and providing rapid, location-independent and top-tier diagnostics by experts.

Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.

Research association - 24/07/2024

SPI-MP: pioneer in personalised medical technology

Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

BioRegio STERN Management GmbH is a partner in the new RehAllianCE project, which is being funded by the EU as part of the Interreg CENTRAL EUROPE program. The focus is on the use of new technologies in rehabilitation to improve patient care. The aim is to increase the innovation capacities of SMEs so that aids such as rehabilitation robots, exoskeletons etc. can be used more quickly.

Baden-Württemberg receives the EU Commission's "Regional Innovation Valley" label - 01/07/2024

Customised healthcare for all: BIOPRO is a partner in the EU project PRECISEU

The EU research project PRECISEU, which started in June 2024 and will run for five years, aims to connect innovation ecosystems across Europe and advance personalised medicine throughout Europe. BIOPRO Baden-Württemberg is one of 25 partner organisations from 11 European countries that are working on the further development of customised healthcare as part of the research project.

How can we use artificial intelligence (AI) to make comprehensible medical decisions? A new project at the University of Mannheim, which has received funding from the Federal Ministry of Education and Research (BMBF), will analyze this question.

Gender-specific differences - 18/06/2024

Gender medicine: Why is good healthcare not a matter of course for everyone?

Gender medicine is the study of gender-specific health differences. Many diseases manifest themselves differently in men and women and therapies do not always have the same effect depending on the sex of the patient being treated. There is currently not enough data on these differences. Research teams including the one led by Professor Dr. Dr. Sonja Loges from the University Medical Centre Mannheim and the DKFZ are seeking to change this.

Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.

Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.

Innovation in emergency medicine - 23/05/2024

CARL pushes back the boundaries of resuscitation therapy

Few people survive a cardiac arrest; blood stops flowing to the brain and other vital organs and the resulting lack of oxygen causes extensive damage to the body. In response to this, researchers at the University Medical Centre Freiburg and Resuscitec GmbH have developed CARL, an innovative resuscitation system, which – in addition to the oxygen level – adjusts numerous blood parameters to individual patient requirements. This greatly improves…

App for tuberculosis diagnosis - 15/05/2024

"Find-TB" aims to improve access to tuberculosis diagnostics

Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.

The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform.

With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.

Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells.

Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.

Health Data Futures project - 11/01/2024

Creating a network of trust

In the three-nation project "Health Data Futures", stakeholders and experts from Germany, France and Switzerland have launched a series of patient-centred innovations. Using various future scenarios, the project partners may be able to come up with even more scenarios.

A research team of scientists from the Fraunhofer IPA, the Bosch Digital Innovation Hub at Bosch Health Campus and the Institute of Image-Guided Surgery (IHU) of Strasbourg has jointly launched the DAIOR project. Within the framework of the project, the project partners are working on realizing the operating room of the future with help of artificial intelligence and robot assisted telemedicine.

Inovedis GmbH’s innovative implant - 28/03/2023

Next-generation minimally invasive shoulder surgery

The treatment of shoulder injuries such as rotator cuff tears is one of the most common orthopaedic interventions. It is therefore quite surprising that the surgical procedure has not changed much for decades - although it is relatively complicated. The start-up Inovedis has now developed a completely new surgical technique based on an implant that can be performed simply, safely, quickly and cost-effectively with minimal stress for patients.

This month marks the launch of an outstanding project integrating artificial intelligence (AI) and neuromedicine – the Hertie Institute for Artificial Intelligence in Brain Health (Hertie AI). Founded on February 1 at the Medical Faculty of the University of Tübingen, it will be the first institute in Germany to research the prevention and early diagnosis of diseases of the nervous system using artificial intelligence methods.

Non-profit limited liability company creates institutional framework for interdisciplinary research collaboration, innovative technology development and outstanding healthcare in the Rhine-Neckar region.

Photon-counting technology - 01/02/2023

PC3 consortium: innovative computed tomography for Baden-Württemberg

The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.

Automated pain recognition - 25/01/2023

Using artificial intelligence to improve pain management

Psychologists from Ulm and their cooperation partners have developed algorithms for automated pain recognition in order to be able to dose painkillers more precisely. The researchers are now looking for industrial partners to take their project to application.

Value-based healthcare - 11/01/2023

High-quality healthcare pays off

High-quality medical treatment is not only worthwhile for ill persons. The Division of Health Economics at the German Cancer Research Center in Heidelberg, headed up by Prof. Dr. Michael Schlander, together with researchers from Dresden, has carried out a cost-effectiveness analysis that shows that certified colon cancer centres provide not only better but also more cost-effective care than other clinics.

On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.